There is an excellent clinical trial finder at TriCanHealth.com. You can look up the different trials for the specific KRAS mutation and it explains the mode of action. There are several KRAS trials using drugs such as RMC-6236 which is a pan KRAS inhibitor drug. It has the ability to target a wide number of KRAS variants whereas drugs line RMC-9805 and MRTX-1133 target a specific KRAS mutation-in this case G12D. Some trials combine drugs to see if a synergistic effect is obtained. An example is a trial by Revolution Medicine combining RMC-6236 and RMC-9805 to see if enhanced efficacy is achieved over monotherapy with either drug. In the trial descriptor using TriCanHealth.com or clinicaltrials.gov, there will be a section describing mode of action and trial objective.

There is growing evidence suggesting a survival benefit with aggressive treatment in patients with oligometastatic pancreatic cancer. However, careful patient selection is critical to avoid causing more harm than benefit. Ideally, I like to see that the patient has undergone at least 6 to 12 months of systemic therapy with no evidence of disease progression before considering such an approach.